160 related articles for article (PubMed ID: 18025258)
1. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.
Zhou Z; Reddy K; Guan H; Kleinerman ES
Mol Cancer Res; 2007 Nov; 5(11):1125-32. PubMed ID: 18025258
[TBL] [Abstract][Full Text] [Related]
2. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
Zhou Z; Bolontrade MF; Reddy K; Duan X; Guan H; Yu L; Hicklin DJ; Kleinerman ES
Clin Cancer Res; 2007 Aug; 13(16):4867-73. PubMed ID: 17699866
[TBL] [Abstract][Full Text] [Related]
3. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
Dalal S; Berry AM; Cullinane CJ; Mangham DC; Grimer R; Lewis IJ; Johnston C; Laurence V; Burchill SA
Clin Cancer Res; 2005 Mar; 11(6):2364-78. PubMed ID: 15788688
[TBL] [Abstract][Full Text] [Related]
5. Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma.
Jia SF; Duan X; Worth LL; Guan H; Kleinerman ES
Cancer Gene Ther; 2006 Oct; 13(10):948-57. PubMed ID: 16763609
[TBL] [Abstract][Full Text] [Related]
6. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
Strammiello R; Benini S; Manara MC; Perdichizzi S; Serra M; Spisni E; Picci P; Scotlandi K
Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346
[TBL] [Abstract][Full Text] [Related]
7. Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor.
Csaky KG; Baffi JZ; Byrnes GA; Wolfe JD; Hilmer SC; Flippin J; Cousins SW
Exp Eye Res; 2004 Jun; 78(6):1107-16. PubMed ID: 15109917
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.
Zhou RR; Jia SF; Zhou Z; Wang Y; Bucana CD; Kleinerman ES
Cancer Gene Ther; 2002 May; 9(5):407-13. PubMed ID: 11961663
[TBL] [Abstract][Full Text] [Related]
9. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas.
Yu L; Su B; Hollomon M; Deng Y; Facchinetti V; Kleinerman ES
Cancer Res; 2010 Feb; 70(4):1334-43. PubMed ID: 20124484
[TBL] [Abstract][Full Text] [Related]
10. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration.
Morales-Arias J; Meyers PA; Bolontrade MF; Rodriguez N; Zhou Z; Reddy K; Chou AJ; Koshkina NV; Kleinerman ES
Cancer; 2007 Oct; 110(7):1568-77. PubMed ID: 17694551
[TBL] [Abstract][Full Text] [Related]
11. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor.
Reddy K; Zhou Z; Jia SF; Lee TH; Morales-Arias J; Cao Y; Kleinerman ES
Int J Cancer; 2008 Aug; 123(4):831-7. PubMed ID: 18537159
[TBL] [Abstract][Full Text] [Related]
12. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
[TBL] [Abstract][Full Text] [Related]
13. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature.
Reddy K; Cao Y; Zhou Z; Yu L; Jia SF; Kleinerman ES
Angiogenesis; 2008; 11(3):257-67. PubMed ID: 18344025
[TBL] [Abstract][Full Text] [Related]
14. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature.
Lee TH; Bolontrade MF; Worth LL; Guan H; Ellis LM; Kleinerman ES
Int J Cancer; 2006 Aug; 119(4):839-46. PubMed ID: 16557578
[TBL] [Abstract][Full Text] [Related]
15. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM
J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596
[TBL] [Abstract][Full Text] [Related]
16. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
[TBL] [Abstract][Full Text] [Related]
17. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes.
Aghi M; Cohen KS; Klein RJ; Scadden DT; Chiocca EA
Cancer Res; 2006 Sep; 66(18):9054-64. PubMed ID: 16982747
[TBL] [Abstract][Full Text] [Related]
18. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo.
Raskopf E; Vogt A; Sauerbruch T; Schmitz V
J Hepatol; 2008 Dec; 49(6):977-84. PubMed ID: 18845354
[TBL] [Abstract][Full Text] [Related]
19. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.
Chernoguz A; Crawford K; Donovan E; Vandersall A; Berglund C; Cripe TP; Frischer JS
J Surg Res; 2012 Mar; 173(1):1-9. PubMed ID: 21658718
[TBL] [Abstract][Full Text] [Related]
20. Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice.
He XW; Yu X; Liu T; Yu SY; Chen DJ
Chin Med J (Engl); 2008 Mar; 121(5):439-44. PubMed ID: 18364118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
